GeneFab is seeking an experienced Downstream Process Development Scientist/Lead focused on viral vector purification (AAV and Lentiviral) for in vivo gene therapy. It is a technical, project-based role within a CRDMO environment that balances hands-on process optimization with cross-functional leadership and client-facing responsibilities.
Responsibilities
- Design, optimize, and scale-up downstream processes for the purification of viral
vectors, with a focus on in vivo gene therapy products and lentiviral vectors.
- Execute experimental plans, analyze data, and provide insightful
recommendations to improve process efficiency, yield, and product quality.
- Collaborate with cross-functional teams, including Upstream Process
Development, Analytical Development, and Manufacturing, to ensure seamless
integration of processes.
- Troubleshoot and resolve technical challenges in downstream processes, ensuring
robust and scalable solutions.
- Present internally and to client with project status updates
- Stay abreast of industry trends, emerging technologies, and regulatory guidelines
to contribute to the continuous improvement of processes and compliance.
- Provide direction and leadership to development associates as the team expands.
Qualifications
- Ph.D. or Master’s degree in Chemical Engineering, Biochemical Engineering,
Biotechnology, or related field with a minimum of 3 years (Ph.D.) or 5 years
(Master’s) of relevant industry experience
- Proven expertise in downstream process development for viral vectors, with a
focus on AAV and lentiviral vectors.
- Hands-on experience with chromatography, filtration, TFF and other downstream
processing techniques.
- Strong analytical and problem-solving skills, with the ability to interpret complex
data sets.
- Excellent communication skills and the ability to work collaboratively in a team
environment.
- Knowledge of regulatory requirements and quality standards related to
biopharmaceutical manufacturing.
- Experience with formulation science preferred
$130,000 - $150,000 a year
About GeneFab
GeneFab is a contract manufacturing and synthetic biology biofoundry focused on cell and gene therapies. GeneFab was formed in 2023 with a vision to combine industry leading expertise in synthetic biology with advanced cGMP capabilities in order to accelerate the development and commercialization of genetic medicines. GeneFab offers its customers an extensive technology platform and know-how that spans early stage product design, technical development, and cGMP compliant production. GeneFab's technology platform includes bioinformatic-guided discovery of cell type promoters, directed evolution of small molecule-regulated gene switches, and the engineering of highly sensitive kill switches for enhanced safety and control of cellular therapies.
We are committed to an inclusive and diverse GeneFab. We believe that different perspectives lead to better ideas, and better ideas allow us to better understand the needs and interests of our diverse GeneFab team. We welcome people of different backgrounds, experiences, abilities, and perspectives and are an equal opportunity employer.
We may use artificial intelligence (AI) tools to support parts of the hiring process, such as reviewing applications, analyzing resumes, or assessing responses and identifying potential inconsistencies or verification signals in application materials based on available information. These tools assist our recruitment team but do not replace human judgment. Final hiring decisions are ultimately made by humans. If you would like more information about how your data is processed, please contact us.